Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 14/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2439543 | 0.84 | KDM4E (0.46) | CYP17A1ROCK2NAMPTGAANPC1 | |
| SCHEMBL2442485 | 0.82 | ROCK2 (0.59) | ROCK2 | |
| SCHEMBL2476502 | 0.82 | ROCK2 (0.51) | ROCK2 | |
| SCHEMBL14245397 | 0.80 | NAMPT (0.48) | CYP17A1ROCK2NAMPT | |
| SCHEMBL2478782 | 0.78 | ROCK2 (0.48) | ROCK2 | |
| SCHEMBL31733813 | 0.76 | MAPT (0.41) | GAAAAK1 | |
| SCHEMBL2441134 | 0.76 | MAPT (0.41) | GAAAAK1 | |
| SCHEMBL31733386 | 0.75 | NOTUM (0.47) | GAAAAK1 | |
| SCHEMBL1345706 | 0.74 | GPR139 (0.43) | AAK1 | |
| SCHEMBL1345707 | 0.74 | GPR139 (0.43) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912209-B2 | Rock inhibitors | AMAKEM NV (BE) | 2014-12-16 | — | — | US | disclosed |
| US-8912209-B2 | Rock inhibitors | AMAKEM NV (BE) | 2014-12-16 | — | — | US | disclosed |
| US-8912209-B2 | Rock inhibitors | AMAKEM NV (BE) | 2014-12-16 | — | — | US | disclosed |
| US-8815873-B2 | Heterocyclic amides as rock inhibitors | AMAKEM NV (BE) | 2014-08-26 | — | — | US | disclosed |
| US-8815873-B2 | Heterocyclic amides as rock inhibitors | AMAKEM NV (BE) | 2014-08-26 | — | — | US | disclosed |
| US-8815873-B2 | Heterocyclic amides as rock inhibitors | AMAKEM NV (BE) | 2014-08-26 | — | — | US | disclosed |
| US-20130252975-A1 | NOVEL ROCK INHIBITORS | AMAKEM NV (BE) | 2013-09-26 | — | — | US | disclosed |
| US-20130252975-A1 | NOVEL ROCK INHIBITORS | AMAKEM NV (BE) | 2013-09-26 | — | — | US | disclosed |
| US-20130252975-A1 | NOVEL ROCK INHIBITORS | AMAKEM NV (BE) | 2013-09-26 | — | — | US | disclosed |
| CN-103316000-A | Heterocyclic amides as ROCK inhibitors | AMAKEM NV | 2013-09-25 | — | — | CN | disclosed |
| EP-2626348-A1 | Heterocyclic amides as rock inhibitors | Amakem NV (BE) | 2013-08-14 | — | — | EP | disclosed |
| EP-2626348-A1 | Heterocyclic amides as rock inhibitors | Amakem NV (BE) | 2013-08-14 | — | — | EP | disclosed |
| EP-2542528-B1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2013-06-19 | — | — | EP | disclosed |
| EP-2542528-B1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2013-06-19 | — | — | EP | disclosed |
| EP-2542528-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | Amakem NV (BE) | 2013-01-09 | — | — | EP | disclosed |
| US-20120322801-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2012-12-20 | — | — | US | disclosed |
| US-20120322801-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2012-12-20 | — | — | US | disclosed |
| US-20120322801-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2012-12-20 | — | — | US | disclosed |
| WO-2011107608-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011107608-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | AMAKEM NV (BE) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322801-A1 | HETEROCYCLIC AMIDES AS ROCK INHIBITORS | ROCK1, ROCK2, CIT | CYP17A1 136/4885ROCK2 2/4885NAMPT 1112/4885 |
| US-20130252975-A1 | NOVEL ROCK INHIBITORS | ROCK1, ROCK2, CIT | CYP17A1 166/4885ROCK2 2/4885NAMPT 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.